Carbidopa
Active ingredient
Sold as CREXONT · APO-LEVOCARB · JAMP LEVOCARB
- Drug class
- -
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 116
- FDA reports (12 mo)
- 2,971
Overview
Plain-language summary, compiled from the cited regulatory records
Carbidopa is an active pharmaceutical ingredient used in combination with levodopa [1]. It is approved for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may occur after carbon monoxide or manganese intoxication [1].
Carbidopa is available under various brand names, including CREXONT [1]. In the past 12 months, there have been 2,971 adverse event reports associated with this medication [2]. The most frequently reported adverse events include hallucination, death, fall, drug ineffective, and dyskinesia [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 93 | May 29, 2026 |
| CA Canada | Health Canada | 14 | October 30, 2025 |
| US United States | FDA | 9 | May 29, 2026 |
GBUnited Kingdom· MHRA
93 products
Uses
Idiopathic Parkinson’s disease, in particular to shorten the ‘off’ period in patients who have previously been treated with immediate-release levodopa/decarboxylase inhibitors or with just levodopa and who showed motor fluctuations.
The experience with Lecado is limited in patients, who have not been previously treated with levodopa.
How to take
CACanada· Health Canada
14 products
Uses
pms-LEVODOPA-CARBIDOPA (levodopa and carbidopa tablets) is indicated for the treatment of Parkinson's disease. pms-LEVODOPA-CARBIDOPA is not recommended for the treatment of drug-induced extrapyramidal reactions. 1 Pediatrics Pediatrics (< 18 years of age): The safety and effectiveness of levodopa and carbidopa in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use.
2 Recommended Dose and Dosage Adjustment, Geriatrics).
How to take
USUnited States· FDA
9 products
Uses
1 INDICATIONS AND USAGE CREXONT is indicated for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication in adults. CREXONT is a combination of carbidopa (an aromatic amino acid decarboxylation inhibitor) and levodopa (an aromatic amino acid) indicated for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication in adults.
( 1 )
How to take
Drug interactions
Known interactions involving Carbidopa. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL044160857 · revised May 29, 2026
- [2]Health Canada (DPD) · 02549719 · revised October 30, 2025
- [3]FDA DailyMed · 095a08b6-b0b8-4f… · revised May 29, 2026 [PDF]
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.